Detalhe da pesquisa
1.
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.
Haematologica
; 100(6): 780-5, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25715404